Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison-Reference-Cited by-同舟云学术

Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison

Published:2003-04-11 Issue:6 Volume:11 Page:362-370
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Gorschlüter M.,Hahn C.,Fixson A.,Mey U.,Ziske C.,Molitor E.,Horré R.,Sauerbruch T.,Marklein G.,Schmidt-Wolf I. G. H.,Glasmacher A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-003-0463-7.pdf

Reference22 articles.

1. Bohme A, Shah PM, Stille W, Hoelzer D (1998) Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 3:324–330

2. Charnas R, Luthi AR, Ruch W (1997) Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Pediatr Infect Dis J 16:346–353

3. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39:445–452

4. Cornely OA, Bethe U, Salzberger B, Franzen C, Hartmann P, Steinmetz T, Fatkenheuer G, Seifert H, Diehl V, Schrappe M (2001) Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Ann Hematol 80:103–108

5. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, Furno P, Russo D, D'Antonio D, Ricci P, Martino B, Mandelli F (2001) A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33:1295–1301

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients;Medicine;2020-05-15

2. Decrease in vancomycin-resistantEnterococcuscolonization associated with a reduction in carbapenem use as empiric therapy for febrile neutropenia in patients with acute leukemia;Infection Control & Hospital Epidemiology;2019-05-03

3. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia;Cochrane Database of Systematic Reviews;2013-06-29

4. Antibiotic Therapy in Neutropenic Patients;Pulmonary Involvement in Patients with Hematological Malignancies;2010-12-22

5. β‐Lactam Antibiotics;Burger's Medicinal Chemistry and Drug Discovery;2010-09-15